ThyGeNEXT
Commercial- Indications
- Thyroid cancer
Company intelligence / Profile preview
Interpace Biosciences offers five commercialized molecular diagnostic tests—PancraGEN®, PanDNA®, ThyGeNEXT®, ThyraMIR®v2, RespriDX®—for the early diagnosis and risk assessment of various cancers. BarreGEN® is currently in a clinical evaluation program for Barrett’s Esophagus. The company reported record revenue growth and profitability in 2024 driven by strong demand for its thyroid nodule assays.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Interpace Biosciences.